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Germline Mutation in ATR in Autosomal-
Dominant Oropharyngeal Cancer Syndrome
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Yuhki Yanase,2 Michihiro Hide,2 Jeffrey Callen,3 and John A. McGrath1,*
ATR (ataxia telangiectasia and Rad3 related) is an essential regulator of genome integrity. It controls and coordinates DNA-replication
origin firing, replication-fork stability, cell-cycle checkpoints, and DNA repair. Previously, autosomal-recessive loss-of-function muta-
tions in ATR have been demonstrated in Seckel syndrome, a developmental disorder. Here, however, we report on a different kind of
genetic disorder that is due to functionally compromised ATR activity, which translates into an autosomal-dominant inherited disease.
The condition affects 24 individuals in a five-generation pedigree and comprises oropharyngeal cancer, skin telangiectases, and mild
developmental anomalies of the hair, teeth, and nails. We mapped the disorder to a ~16.8 cM interval in chromosomal region 3q22–
24, and by sequencing candidate genes, we found that ATR contained a heterozygous missense mutation (c.6431A>G [p.Gln2144Arg])
that segregated with the disease. The mutation occurs within the FAT (FRAP, ATM, and TRRAP) domain—which can activate p53—of
ATR. The mutation did not lead to a reduction in ATR expression, but cultured fibroblasts showed lower p53 levels after activation of
ATR with hydroxyurea than did normal control fibroblasts. Moreover, loss of heterozygosity for the ATR locus was noted in oropharyn-
geal-tumor tissue. Collectively, the clinicopathological and molecular findings point to a cancer syndrome and provide evidence impli-
cating a germline mutation in ATR and susceptibility to malignancy in humans.All cells possess complex mechanisms that respond to and
repair DNA damage. Integral to regulating the DNA-
damage response are the phosphatidylinositol-3-kinase-
related protein kinases (PI3KKs), which include ataxia
telangiectasia mutated (ATM) and ataxia telangiectasia
and Rad3-related (ATR).1,2 These kinases can phosphory-
late and activate several downstream proteins, including
Chk1, Chk2, and p53, that are implicated in cell-cycle
arrest, DNA repair, and apoptosis.1,2 ATM and ATR share
significant sequence homology as well as several biochem-
ical and functional similarities in promoting cell-cycle
arrest and DNA repair. However, whereas ATM is activated
after DNA double-strand breakage, ATR is activated by
single-stranded regions of DNA generated, for example,
in S-phase after replication-fork stalling or during the
repair of certain types of DNA damage.2,3 Notably, ATR is
vital for replicating cell viability, but ATM is not.4–6 Abnor-
malities in DNA-damage checkpoint kinases have been
implicated in cancer biology, and somatic mutations in
ATR (MIM 601215), ATM (MIM 607585), CHK1 (MIM
603078), CHK2 (MIM 604373), BRCA1 (MIM 113705),
and BRCA2 (MIM 600185) have all been observed in
a variety of malignant human tumors.7–11 Germline muta-
tions in both ATM and ATR, however, have also been re-
ported but are associated with clinically distinct congenital
disorders. Autosomal-recessive mutations in ATM underlie
ataxia telangiectasia (MIM 208900), a progressive neurode-
generative condition associated with Purkinje neuron loss,
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Furthermore, heterozygous carriers of ATM mutations
also exhibit increased risk for nonhematologic cancers.13
Mutations in ATR aremuch rarer. To date, a single homozy-
gous synonymousmutation, which is inherited in an auto-
somal-recessive manner and which causes mis-splicing of
exon 9 of ATR, has been described in two related families
afflicted with Seckel syndrome (MIM 210600), which
affects five individuals in total.14 Seckel syndrome is char-
acterized by intrauterine-growth retardation, dwarfism,
microcephaly with intellectual disability, and a character-
istic ‘‘bird-headed’’ facial appearance. Seckel syndrome is,
however, genetically heterogeneous, and five recorded
loci and three known genes (ATR, CENPJ [MIM 609279],
and CEP152 [MIM 613529]) associated with the syndrome
contain pathogenic mutations. Cells derived from individ-
uals with Seckel syndrome resulting from ATR mutations
exhibit reduced expression of ATR and impaired DNA-
damage-induced phosphorylation of important ATR
substrates, including H2AX, Chk1, NBS1, and p53, along
with defective ATR-dependent G2-M cell-cycle checkpoint
activation.14 Considering the fundamental role of ATR in
maintaining replication-fork stability and preserving
genomic integrity, it is perhaps surprising that, to date, in-
herited mutations in ATR, i.e., in individuals with Seckel
syndrome, have not been implicated in malignancy. In
contrast, we now report on a pedigree with an auto-
somal-dominant disorder that reveals a germline mutation
in ATR in a hereditary cancer syndrome.London SE1 9RT, UK; 2Department of Dermatology, Graduate School of
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We investigated a Caucasian family containing 24
affected individuals spanning five generations originating
from Indiana, USA (Figure 1A). All those with the disorder
had telangiectases (Figures 1B, 1C, and 1D) that appeared
during infancy (<18 months) in both sun-exposed and
sun-protected sites; <18 months is somewhat earlier than
in most individuals with ataxia telangiectasia due to reces-
sive mutations in ATM. Other clinical features included
thinning of the lateral part of the eyebrows and patchy
alopecia in areas of skin with prominent telangiectases.
Thin dental enamel and dental caries in both primary
and secondary dentition were also noted. With regard to
malignancy, 10 of the 24 cases developed oropharyngeal
cancer (Figures 1A, 1E, 1F, and 1G), typically in the third
decade of life or thereafter. Other malignancies reported
included nonmelanoma skin cancer (basal cell carcinoma,
squamous cell carcinoma, and sebaceous carcinoma) in
three individuals, breast cancer in one individual, and
cervical cancer in one other family member. No further
cutaneous or developmental anomalies were noted (for
additional clinical details, see Tables S1 and S2, available
online).
After obtaining approval from the ethics committee and
informed consent from all subjects, we extracted genomic
DNA from peripheral blood samples from 26 individuals
(13 subjects with clinical features of the disorder and
13 unaffected individuals) in compliance with the
Declaration of Helsinki Principles. The subjects were geno-
typed with the HumanMapping 10K Array version 2 (Affy-
metrix, High Wycombe, UK) according to the manufac-
turer’s protocol. To generate appropriate input files for
the linkage-analysis program Merlin,15 we utilized
ALOHOMORA software.16 Assuming autosomal-dominant
inheritance with complete penetrance, we then carried out
parametric linkage analysis by using the genotyping data
of 13 individuals (7 affected individuals and 6 unaffected
individuals; indicated by asterisks in Figure 1A). Linkage
analysis identified a single significant locus—with a LOD
score of 2.7—in chromosomal region 3q22–24 (Figure 2A).
The peak on chromosome 3 extends from SNP rs722813 to
rs952032 (116–155 cM) (Figure 2B). Additional microsatel-
lite markers were genotyped for fine mapping of this
interval. The primers were obtained from the ABI PRISM
Linkage Mapping Set version 2.5 (Applied Biosystems,
Warrington, UK). The PCR products were analyzed on an
ABI 3730 DNA sequencer with GeneMapper software
version 3.0 (Applied Biosystems). Fine mapping with mi-
crosatellite markers and SNP array data narrowed the
candidate region to a ~16.8 cM interval in region 3q22–
24 between rs712984 and rs951465 (Figure 1A). This
interval contains ~90 genes, including those predicted
in silico (Figure 2C). Candidate-gene analysis was then per-
formed. Potential candidate genes (which were chosen on
the basis of their associated phenotype) included the
following: AMOTL2 (related to angiogenesis), MRAS and
RASA2 (related to oncogenesis), TOPBP1, CEP63, STAG1,
NCK1, PIK3CB, and ATR (which play a role in DNA-damage512 The American Journal of Human Genetics 90, 511–517, March 9response and DNA replication), and NEK11, ANAPC13,
and TFDP2 (which control the cell cycle). All of the candi-
date genes that were sequenced are listed in Table S3. For
sequencing, DNA samples were amplified with published
primers sited in introns flanking individual exons of each
gene.17 However, sequencing the genomic DNA of
clinically affected individuals for all genes in the interval
only disclosed a single heterozygous point mutation
(c.6431A>G in ATR [NCBI RefSeq accession number
NM_001184.3]) that segregated with the disease. This
mutation, which converts a highly evolutionarily
conserved glutamine to arginine at amino acid 2144
(p.Gln2144Arg) (Figure 3C), was present in all the affected
individuals but not in any of the unaffected individuals
(Figures 3A and 3B). The nucleotide substitution was not
found in the screening of 220 ethnically matched control
chromosomes. This mutation occurs within the FAT
(FRAP, ATM and TRRAP) domain of ATR and is positioned
immediately adjacent to a potential phosphorylation site
(SQ/TQ motif) at Ser2143 (Figure 3C). Within the FAT
domain of ATR, phosphorylation of Thr1989 has previ-
ously been implicated in the activation of ATR by the
ATR stimulator TopBP1.18,19 Nevertheless, the function of
the FAT domain of PI3KKs, including ATR specifically,
has not been unequivocally demonstrated experimentally,
although it has been suggested to have some structural
role, possibly in mediating protein-protein interactions.20
Consistent with this suggestion, the FAT domain of ATM
and ATR has been shown to bind to AIMP3 (aminoacyl-
tRNA synthetase-interacting multifunctional protein 3,
previously known as p18), a haploinsufficient tumor
suppressor that can activate p53.21 Another possibility,
extrapolated from studies on ATM, is that the FAT domain
normally loops to have a direct physical interaction with
the kinase domain, thereby stabilizing the whole carboxy
end of the protein and permitting optimal downstream
regulatory activities.22 However, this has yet to be proven
for the FAT domain of ATR. To evaluate the functional
consequences of the mutation, we first used RT-PCR and
immunoblotting to assess ATR-mRNA expression in skin
samples and in cultured fibroblasts and to assess protein
levels in cultured fibroblasts from two affected subjects,
two control skin samples, and one individual with Seckel
syndrome. In our p.Gln2144Arg mutant samples, there
was no reduction in ATR mRNA (Figures S1 and S2) or
ATR levels (c.f. reduced expression in Seckel syndrome,
Figure 3D). Next, on the basis of the clinical feature of
malignancy and existing data implicating AIMP3 in the
normal upregulation of p53 in response to DNA damage,
we examined expression of p53 by immunoblotting in
ATR-mutated fibroblasts; we noted both constitutively
reduced p53 and also reduced p53 levels after ATR activa-
tion with hydroxyurea (Figure 3E). Furthermore, under
similar experimental conditions, hydroxyurea-induced
Chk1 and H2AX phosphorylation did not show any clear
reduction in these ATR-mutated cells, suggesting differen-
tial substrate activation (Figures S3 and S4)., 2012
Figure 1. Pedigree, Linkage Analysis, and Clinicopathological Features of This Autosomal-Dominant Disorder Associated with
a Missense Mutation in ATR
(A) The family pedigree. Squares denote male family members, and circles denote female family members. A 17.3 Mb critical region is
defined by recombination events in individual IV:6 for rs712984 and in individuals IV:3 and IV:12 for SNP rs958465.
(B, C, and D) Carriers are a 6-year-old female (B), a 35-year-old female (C), and a 56-year-old male (D) with telangiectases on the face as
well as thin outer eyebrows.
(E) A 25-year old female carrier with the additional feature of a papillomatous tumor in the upper-pharynx (tonsillar) region with histo-
logical features of squamous cell carcinoma.
(F and G) Histopathological feature of squamous cell carcinoma in the upper pharynx (tonsillar) region of affected individual IV-12. The
epidermis shows full-thickness dysplasia with hyperkeratosis and parakeratosis (hematoxylin and eosin stain; original magnification is
3100) (F). Nests of carcinoma cells are infiltrating into the submucosal tissue (hematoxylin and eosin stain; original magnification is
3200) (G).
Additional pedigree data are detailed in Table S1 and S2.
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Figure 2. Genome-Wide Linkage Analysis
(A) Genome-wide parametric linkage analysis reveals a LOD score of >2.5 on chromosome 3.
(B) Magnification of the LOD-score diagram of the chromosome 3 region. The chromosome 3 peak extends from SNP rs722813 to
rs952032 (116–155 cM), and the max LOD is 2.7. Fine mapping with microsatellite markers and SNP array data (Figure 1A) narrowed
the candidate region to a ~16.8 cM interval in region 3q22–24 between rs712984 and rs951465.
(C) This interval contains ~90 genes, including ATR.Cancer predisposition might be associated with tumor-
suppressor inactivation resulting from both an inherited
mutation (i.e., a mutant allele) in the germline and
a somatic loss of the wild-type allele (such a loss leaves
a single copy of the mutant allele).23 For loss of heterozy-
gosity (LOH) analysis in the cancer tissue of this syndrome,
we sequenced DNA extracted from paraffin sections of an
oropharyngeal-cancer lesion from affected individual
IV-12 (Figures 3A and 3B). Sequencing revealed a homozy-
gous or hemizygous change, c.6431A>G in ATR, in the
cancer lesion. This LOH event, with the allelic loss of the
wild-type ATR allele, does not affect the expression of
ATR by immunohistochemistry (Figure S5) but implicates
ATR in the pathophysiology of the oropharyngeal cancer
and therefore indicates a tumor-suppressing role of ATR.514 The American Journal of Human Genetics 90, 511–517, March 9Nevertheless, this interpretation can only be supported
after further exploration of the occurrence of LOH in
more squamous-cell-carcinoma samples from this pedi-
gree. We also assessed the tumor tissue for the presence
of human papillomavirus (HPV), given that HPV is
a known risk factor for oropharyngeal cancer.24 However,
PCR amplification of tumor DNA via the PCR Human
Papillomavirus Detection Set (Takara, Osaka, Japan) failed
to identify HPV in two oropharyngeal-cancer samples ob-
tained from subjects IV-12 and IV-20 (data not shown).
Germline mutations in ATR have hitherto only been
reported in the autosomal-recessive disorder Seckel
syndrome. Moreover, a humanized mouse model (incorpo-
rating the Seckel-patient-specific mutation) of the disorder
shows similar features—proportionate dwarfism and, 2012
Figure 3. Identification of a Pathogenic Mutation in ATR
(A) Nucleotide sequencing of genomic DNA extracted from the blood of an affected individual reveals a heterozygous missense muta-
tion, c.6431A>G (p.Gln2144Arg), in ATR (‘‘affected blood’’) but a homozygous or hemizygous mutation in an oropharyngeal-cancer
lesion (‘‘affected OPC’’) from carrier individual IV-12.
(B) Analysis of the mutation c.6431A>G in ATR with restriction enzyme MfeI. PCR products from the wild-type (‘‘Wt’’) allele were di-
gested, whereas those from the mutant (‘‘Mt’’) allele were not. Control-blood DNA shows only a digested band (‘‘control blood’’).
DNA extracted from blood shows both an undigested band and a digested band (‘‘IV-12 blood’’) but only an undigested band from
the oropharyngeal-cancer lesion (‘‘IV-12 OPC’’) in carrier individual IV-12.
(C) A schematic representation of ATR (NP_001175.2). The mutation occurs within the FAT domain of ATR. The substituted amino acid
(p.Gln2144) is well conserved throughout various evolutionary lineages.
(D) Immunoblot of ATR in fibroblast extracts. ‘‘NF’’ indicates control fibroblasts from a healthy donor; ‘‘F04-12’’ and ‘‘F04-20’’ are fibro-
blasts from carriers IV-12 and IV-20, respectively, in Figure 1A; ‘‘ATR-S’’ denotes fibroblasts derived from an individual with ATR Seckel
syndrome; MCM2 (minichromosome maintenance complex component 2) was used as a loading control. The antibodies sc-1887 (for
ATR) and sc-9839 (for MCM2) were purchased from Santa Cruz (Santa Cruz, CA).
(E) Immunoblot of p53 in fibroblast extracts (of both carriers and controls) before and after the activation of ATR by hydroxyurea (‘‘HU’’)
exposure for two hours; b-actin was used as a loading control. The antibodies #9282 (for p53) and #4967 (for b-actin) were purchased
from Cell Signaling (Beverly, MA).microcephaly, along with an overt progeroid phenotype
coupled with attenuation of stem-cell niches—to those of
the human syndrome.4,25 Furthermore, conditional partial
deletion of Atr in a postnatal mouse leads to a similar age-
related phenotype—hair graying, alopecia, and thymic
involution—consistent with the loss of stem cell regenera-
tive capacity.4,26 Nevertheless, neither individuals with
Seckel syndrome nor either mouse model display an
elevated incidence of malignancy. This might be related to
the magnitude of ATR deficiency in this context because
heterozygous mutations and haploinsufficiency of ATR
have been implicated in some acquired cancers in certain
circumstances.27 Notably, somatic mutations in exon 10 of
ATR have been detected in some endometrial, colon, and
stomach tumors.27 Thesemutations, which occur upstreamThe Ameof the FAT domain, have been shown to inhibit ATR-depen-
dent responses toDNAdamage. A further study also showed
that ATR haploinsufficiency leads to high-level genetic
instability and accelerated tumorigenesis in a mismatch
repair-deficient host.28 Notably, monoallelic ATR targeting
in MLH1 (MutL homolog 1)-deficient HCT 116 carcinoma
cells resulted in hypersensitivity to genotoxic stress accom-
panied by an increase in fragile-site instability, as well as
chromosomal amplifications and rearrangements.28 Mice
bearing the Atrþ/ Mlh1/ genotype were highly prone to
both embryonic lethality and early tumor development.28
Furthermore, Chk1, an important effector kinase of ATR,
can also act as a haploinsufficient tumor suppressor.29
In contrast, this autosomal-dominant pedigree clearly
provides clinicopathologic data linking an inheritedrican Journal of Human Genetics 90, 511–517, March 9, 2012 515
abnormality in ATR to malignancy. Collectively, our obser-
vations implicate the FAT domain of ATR in the suppres-
sion of tumorigenesis. Why an oropharyngeal-cancer
tumor occurs instead of a hematologic or solid-organ
tumor still remains unclear, and further observation of
this single pedigree will be necessary for establishing
whether there is a more extensive risk of other cancers.
Alternatively, known risk factors for oropharyngeal cancer
include alcohol, tobacco, and viral infections.30 Of these
factors, viral infection might be the most likely cause of
the tumor seen in our pedigree. Notably, the ATR pathway
can be targeted by certain viruses during infection,31 and
viral proteins are ATR targets.32 Regarding the tumor loca-
tion, it has been shown previously that Fanconi anemia—
an autosomal-recessive syndrome caused by defects in at
least 13 proteins that are involved in the recognition and
repair of DNA in a DNA-damage response network and
that are downstream of ATR signaling and are phosphory-
lated by ATR—is also associated with oropharyngeal
cancer.33,34 In conclusion, our report identifies an auto-
somal-dominant disorder and also provides further clinical
and genetic data associating ATR with human disease.Supplemental Data
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